Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that CEO Arthur Sands will present at two virtual conferences in March 2021. The first is the Guggenheim Targeted Protein Degradation Day on March 16, where he will participate in a panel discussion from 10:30 - 11:30 AM EDT. The second is the Oppenheimer 31st Annual Healthcare Conference on March 17 at 3:10 - 3:40 PM EDT, featuring a corporate presentation. Both events will be webcast live, with recordings available post-event on the Nurix website.

Nurix Therapeutics (Nasdaq: NRIX) has announced the pricing of its upsized public offering of 4,500,000 shares at $31.00 each, totaling gross proceeds of approximately $139.5 million. The offering, which includes a 30-day option for underwriters to purchase an additional 675,000 shares, is set to close on March 9, 2021. Notably, this offering aims to enhance the company’s financial flexibility to advance its pipeline of targeted protein modulation therapies.

Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced a public offering of 4,000,000 shares of its common stock, with plans to grant underwriters a 30-day option for an additional 600,000 shares. The offering is managed by J.P. Morgan, Piper Sandler, and Stifel, subject to market conditions. A registration statement has been filed with the SEC but is not yet effective, and the offering is only made by means of a prospectus.

Nurix Therapeutics (Nasdaq: NRIX) reported positive developments, including FDA clearance for its first IND application for NX-2127 targeting B-cell malignancies. The company also expanded its collaboration with Sanofi, resulting in a $22 million option exercise payment. Financially, Nurix ended 2020 with $372 million in cash and investments, up from $38.2 million in 2019. However, the company reported a net loss of $43.2 million for the fiscal year. Upcoming clinical trials for NX-2127 and NX-1607 are expected in 2021, indicating a promising year ahead.

Nurix Therapeutics, Inc. (NRIX) announced an expansion of its collaboration with Sanofi, resulting in an additional payment of $22 million. This follows an upfront payment of $55 million received earlier. Sanofi will now explore five targets instead of three within this agreement. Nurix stands to gain up to $2.5 billion in total payments based on milestones in research and development. CEO Arthur T. Sands highlighted the productive nature of the collaboration, emphasizing progress in drug development for challenging diseases.

Nurix Therapeutics (NRIX) announced that CEO Arthur Sands will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 p.m. EST. The presentation will be available via live webcast, with an archived version accessible for 30 days post-event. Nurix focuses on developing targeted protein modulation therapies for cancer and immune disorders, utilizing its proprietary DELigase platform to discover novel drug candidates.

Nurix Therapeutics (NRIX) announced key preclinical data for NX-2127, targeting B-cell malignancies, at the 62nd American Society of Hematology Annual Meeting. The company plans to initiate a Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia in H1 2021. NX-2127 is designed to overcome resistance in B-cell cancers by degrading Bruton’s tyrosine kinase (BTK) and activating T-cells, showing promising anti-tumor effects in preclinical models.

Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical firm, has announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference will take place from November 16-18, 2020, with CEO Arthur Sands presenting on November 17 at 3:20 p.m. EST. The Piper Sandler 32nd Annual Virtual Healthcare Conference will follow from December 1-3, 2020, featuring Sands on December 1. Both presentations will be available for 30 days afterward on Nurix's Events and Presentations page.

Nurix Therapeutics (NRIX) announced presentations at two significant upcoming events: the 5th Medicinal Chemistry & Protein Degradation Summit and the 62nd ASH Annual Meeting. Key highlights include data on their targeted protein degradation platform and preclinical data for NX-2127, aimed at treating B-cell malignancies. The summit presentation is by Senior Scientist Dan Robbins on November 16, focusing on new therapeutic discovery, while the ASH meeting will feature NX-2127's effects on B-cell malignancies on December 7.